Testing effectiveness (Phase 2)Looking for participantsNCT02559778What this trial is testingPediatric Precision Laboratory Advanced Neuroblastoma TherapyWho this might be right forNeuroblastoma Giselle Sholler 500
Testing effectiveness (Phase 2)Looking for participantsNCT07537400What this trial is testingPatients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5Who this might be right forHigh-Risk Neuroblastoma Shaare Zedek Medical Center 10
Large-scale testing (Phase 3)Looking for participantsNCT06172296What this trial is testingDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaWho this might be right forGanglioneuroblastoma, NodularNeuroblastoma National Cancer Institute (NCI) 478
Large-scale testing (Phase 3)Looking for participantsNCT03126916What this trial is testingTesting the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Who this might be right forGanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma Children's Oncology Group 750
Not applicableStudy completedNCT00002485What this trial is testingDevelopment of Strategies to Increase Enrollment in Clinical Trials for Children With CancerWho this might be right forBrain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+8 more Children's Oncology Group 359
Early research (Phase 1)Study completedNCT00003141What this trial is testingChemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord TumorsWho this might be right forBrain TumorsCentral Nervous System TumorsNeuroblastoma+1 more Children's Oncology Group 94
Testing effectiveness (Phase 2)Study completedNCT00005955What this trial is testingTemozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS TumorsWho this might be right forBrain and Central Nervous System TumorsNeuroblastoma Duke University
Early research (Phase 1)Study completedNCT00638898What this trial is testingBusulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid TumorWho this might be right forSolid TumorAdult Central Nervous System Germ Cell TumorAdult Rhabdomyosarcoma+27 more City of Hope Medical Center 25
Early research (Phase 1)Study completedNCT00070200What this trial is testingInduction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive NeuroblastomaWho this might be right forNeuroblastoma Children's Oncology Group 31
Large-scale testing (Phase 3)Ended earlyNCT01132547What this trial is testingCyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerWho this might be right forCancer University of South Florida 22
Testing effectiveness (Phase 2)UnknownNCT02771743What this trial is testingResponse-based Treatment of High-risk NeuroblastomaWho this might be right forNewly Diagnosed High Risk Neuroblastoma Samsung Medical Center 54
Testing effectiveness (Phase 2)Study completedNCT00003846What this trial is testingRadiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal TumorsWho this might be right forBrain and Central Nervous System TumorsNeuroblastoma Children's Oncology Group 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06948994What this trial is testingA Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory NeuroblastomaWho this might be right forNeuroblastomaGD2 AntibodyAutologous NK Cell Guangzhou Women and Children's Medical Center 15
Testing effectiveness (Phase 2)Study completedNCT00005952What this trial is testingTemozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid TumorsWho this might be right forBrain and Central Nervous System TumorsChildhood Germ Cell TumorHead and Neck Cancer+5 more Duke University 30
Testing effectiveness (Phase 2)Study completedNCT00003203What this trial is testingCarboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal TumorsWho this might be right forBrain TumorsCentral Nervous System TumorsNeuroblastoma Children's Oncology Group 168
Early research (Phase 1)Study completedNCT01798004What this trial is testingBusulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaWho this might be right forGanglioneuroblastomaStage 1 NeuroblastomaStage 2 Neuroblastoma+5 more Children's Oncology Group 150
Very early researchEnded earlyNCT00499733What this trial is testingCyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerWho this might be right forCancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)WithdrawnNCT06858501What this trial is testingComparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk NeuroblastomaWho this might be right forGanglioneuroblastomaGanglioneuroblastoma, NodularHigh Risk Neuroblastoma Children's Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT02641782What this trial is testingNB2013-HR German (GPOH) / Dutch (DCOG) TrialWho this might be right forNeuroblastoma University of Cologne 3
Testing effectiveness (Phase 2)Study completedNCT03786783What this trial is testingDinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaWho this might be right forGanglioneuroblastomaHigh Risk Neuroblastoma National Cancer Institute (NCI) 42